GSK announces that the European Commission has approved a new single-dose, ready-to-use presentation of Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine.

This version is approved for the active immunization of children from the age of 2, adolescents and adults, simplifying administration for healthcare professionals.

GSK's submission is based on two Phase IIb trials demonstrating comparable immunogenicity, tolerability and safety profile to the existing version.

Philip Dormitzer, Head of Vaccines R&D at GSK, underlines the company's commitment to innovation to increase access to vaccination against bacterial meningitis in the European Union.

Copyright (c) 2024 CercleFinance.com. All rights reserved.